|Brand name(s), other common name(s)||Neulasta®, G-CSF|
|Biosimilar* name||Pegfilgrastim-jmdb (FulphilaTM), Pegfilgrastim-cbqv (UdenycaTM), Pegfilgrastim-bmez (ZiextenzoTM)|
|Drug type||Growth factor|
|How the drug is given||Subcutaneous (SC) injection or intravenously (IV); subcutaneously via the On-body Injector which is co-packaged with a single prefilled syringe|
Indications and Usage
Pegfilgrastim is FDA approved to
- Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
- Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).
Limitations of Use: Pegfilgrastim is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation
Side effects needing medical attention
Pain in the bones, arms, and legs; spleen rupture; Acute Respiratory Distress Syndrome (ARDS); allergic reactions such as rash, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating; sickle cell crisis; kidney injury; increased white blood cell count (leukocytosis); and Capillary Leak Syndrome.
*A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. Click here for more information.